Live Vaccines and Innate Immune Training in COPD.

Launched by JOSEFIN EKLÖF · Feb 6, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Live Vaccines and Innate Immune Training in COPD," is exploring whether vaccinations with weakened live vaccines can help improve the immune system of patients with Chronic Obstructive Pulmonary Disease (COPD). The goal is to see if these vaccines can trigger a response in the immune system that benefits patients. This study is currently looking for participants who are at least 40 years old, have been diagnosed with COPD, and are able to provide informed consent. However, individuals with certain health conditions, recent vaccinations, or specific allergies won't be eligible to join.

If you participate in this trial, you'll receive a live vaccine, and researchers will monitor your health to see how your immune system responds. The study is designed to gather information that could lead to better ways of managing COPD in the future. It's important to note that participation is voluntary, and you can ask questions or withdraw at any time. Your involvement could help advance our understanding of COPD and improve treatments for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Specialist verified and spirometry-confirmed COPD
• • Age \> 40 years.
• • Negative HIV-test.
• • Able to give informed consent.
• Exclusion Criteria:
• • Acute febrile illness.
• • Known allergy to BCG or MMR vaccines or serious adverse effects at previous vaccination.
• • Allergy to MMR vaccine components, neomycin, or egg proteins.
• • Known prior, active, or latent infection with mycobacterium tuberculosis.
• • Pregnancy or breastfeeding.
• • Vaccination with a live vaccine within the last 4 weeks.
• • Being severely immunocompromised (HIV-1 infection, organ- or bone marrow transplantation, chemotherapy, primary immune defect, anti-cytokine therapy, immunosuppressant treatment).
• • Oral or intravenous corticosteroid at dose of ≥10 mg/day with duration over 3 months.
• • Active solid or non-solid malignancy or lymphoma, excluding basal cell carcinoma within 2 years.
• • Treatment with immunoglobulins within the last 3 months or expected treatment with immunoglobulins for the duration of the trial.